Navigation Links
Bionovo Announces 2009 Highlights and Year-End Financial Results
Date:3/15/2010

--- --- Total assets $24,149 $22,504 ======= ======= LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Accounts payable $311 $521 Accrued compensation and benefits 367 456 Current portion of lease obligations 476 682 Current portion of notes payable 59 - Other current liabilities 823 668 --- --- Total current liabilities 2,036 2,327 Non-current portion of lease obligations 96 545 Non-current portion of notes payable 121 - --- -- Total liabilities 2,253 2,872 ----- ----- Commitments and contingencies Shareholders’ equity: Preferred stock, $0.0001 par value; 10,000,000 shares authorized; none issued and outstanding - - Common stock $0.0001 par value, 190,000,000 shares authorized, 107,518,690 and 76,363,101 shares outstanding at December 31, 2009 and 2008, respectively 11 8 Additional paid-in cap
'/>"/>
SOURCE Bionovo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Bionovo, Inc. to Announce Fourth Quarter and Fiscal Year 2009 Financial Results on Monday, March 15, 2010
2. Bionovo Announces Publication of Positive Results From the Phase 1B Clinical Trial of Bezielle (BZL101) for Metastatic Breast Cancer
3. Bionovo Announces Third Quarter 2009 Highlights and Financial Results
4. Bionovo, Inc. to Announce Third Quarter Fiscal Year 2009 Financial Results on Thursday, November 5, 2009
5. Bionovo Announces Publication of Data on Potential Increase in Breast Cancer Risk Due to the Inhibitory Effect of Tamoxifen Treatment on Estrogen Receptor Beta
6. Bionovo Announces Second Quarter 2009 Highlights and Financial Results
7. Bionovos Estrogen Receptor Beta Selective Drugs Have Unique Gene Expression and Cell Type Specificity
8. Bionovo Announces First Quarter 2009 Highlights and Financial Results
9. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
10. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
11. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013 Fuse Science, Inc. (OTCQB: ... company that is developing new, patent-pending technologies poised to redefine ... that it will hold a business update teleconference and webcast ... nd , 2013 at 4:30 PM ET. ... will host the call and will be joined by ...
(Date:5/17/2013)... 2013  PENTAX Medical, a healthcare industry leader ... leader in ultrasound imaging, recently announced renewed collaborative ... further innovation in the development of Endoscopic Ultrasound ... and PENTAX Medical endoscopic portfolio have formed one ... systems. This agreement will continue to grow their ...
(Date:5/17/2013)... -- Sanofi (EURONEXT: SAN and NYSE: SNY ) announced ... , examining the selective JAK2 inhibitor SAR302503 for myelofibrosis ... The primary endpoint assessed the proportion of patients achieving ... in previous trials, the most common adverse events were ... presented at an upcoming medical congress. ...
Breaking Medicine Technology:Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 2PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6
(Date:5/17/2013)... HealthDay Reporter , , FRIDAY, May 17 (HealthDay News) ... brain may make the call on which ear you ... The dominant side of your brain is where your ... human population is left-brain dominant, and those people tend ... who are right-brain dominant. In this study, scientists found ...
(Date:5/17/2013)... 17, 2013 Fighting addiction is hard ... for diabetics, treatment is more difficult and complicated. Drug ... to monitor blood sugar levels and administer insulin when ... drug rehab for diabetics needs to have ... needs of the diabetic, and has experience caring for ...
(Date:5/17/2013)... 17 (HealthDay News) -- Teen bullies are more likely ... finds. UT Dallas researchers analyzed several decades of ... All of them had similar working-class backgrounds and most ... were in their mid-50s. Nearly half of the ... years engaged in some form of criminal activity -- ...
(Date:5/17/2013)... SportsFanPlayground.com is currently offering a new ... $319.99, nearly 20% off of the retail price. , The ... Adventures and Carnival Games, and a complementary 3-month Xbox Live ... Kinect Star Wars Bundle available for shipping. The Star Wars bundle ... 360 console, a custom white Kinect sensor, an Xbox 360 wired ...
(Date:5/17/2013)... Guide to the DSM-5 explores all revisions to ... Manual, and shows clinicians how they can best ... most contentious resource. Written by a celebrated professor ... and new research to point out where DSM-5 ... the jury,s still out. Along the way, The ...
Breaking Medicine News(10 mins):Health News:Cellphone Use May Reveal Your 'Dominant Brain' 2Health News:Cellphone Use May Reveal Your 'Dominant Brain' 3Health News:Above It All Treatment Center Helps Drug Addicts who are Type I and Type II Diabetics 2Health News:Above It All Treatment Center Helps Drug Addicts who are Type I and Type II Diabetics 3Health News:Xbox 360 Kinect Bundle 20% Off at SportsFanPlayground.com 2
... are banned for manufacture, import and use in India. ... use in the country but their manufacture is allowed ... to Information (RTI) Act. ,As India grapples ... productivity and environmental safety, the government has also acknowledged ...
... Manipur are literally holding the state to ransom with ... huge extortion notices slapped by rebels. ,Pharmacies ... until Sunday after a rebel group demanded Rs.10 million ... Association and the All Manipur Pharmaceutical and Druggists Association. ...
... poison that can kill, arsenic also can prolong the lives ... new study out Saturday found. ,"This study shows ... earlier in the course of treatment," said Dr. Bayard Powell, ... and the lead author of the research delivered at the ...
... The last two decades have seen modest overall improvements in ... However, according to researchers at The University of Texas M. ... the rates for black women; differences in life expectancy between ... study, presented today (June 3) at the 43rd annual American ...
... the journal Health Psychology, by the American Psychological Association ... or mean disposition tend to have compromised lung ... were ruled out as possible causes of lung dysfunction. ... White 18-30 year olds from four metropolitan areas (sampled ...
... new study co-led by an urologist and a radiation ... specialty of the physician patients see can influence ... analyzed men with localized prostate cancer. It found that ... urologist are more likely to undergo surgery to remove ...
Cached Medicine News:Health News:25 Pesticides Banned in India, Others Face Partial Curbs 2Health News:Manipur Pharmacies Shut Down Fearing Separatist Threats 2Health News:Advanced Breast Cancer: Study Reveals White and Black Women Have Different Survival Rates 2Health News:Unhealthy Lungs Linked to Hostility? 2Health News:Early Prostate Cancer: Specialty of Physician Influences Type of Therapy Received 2Health News:Early Prostate Cancer: Specialty of Physician Influences Type of Therapy Received 3
Patient-Centered Therapy that promotes natural cardiac function....
... The Alliance Catheter Delivery ... manipulation, and stabilization of the ... Alliance CDS has a patented ... for quick and easy access ...
... throughout the world are facing difficult times ... of the blood supply in the face ... donor base. Clearly, these centers must find ... manage their existing donor pools, and to ...
The COBE 2991 Cell Processor provides reliable, automated cell processing, with the control you need to get reproducible results in your lab. This versatile machine offers users reliability and multi...
Medicine Products: